• HA Poirel
  • Marijke Vanspauwen
  • Gilles Macq
  • Anke De Geyndt
  • Johan Maertens
  • Evelyne Willems
  • Dominik Selleslag
  • X Poiré
  • Koen Theunissen
  • Carlos Graux
  • Tessa Kerre
  • Pierre Zachée
  • Nathalie Meuleman
  • Anke Verlinden
  • Florence Van Obbergh
  • Christine Schuermans
  • Virginie De Wilde
  • Aurélie Jaspers
  • Delphine Pranger
  • Dries Deeren
  • Evelien Vaes
  • Yves Beguin

While performance since the introduction of the JACIE quality management system has been shown to be improved for allogeneic hematopoietic stem cell transplants (HSCT), impact on autologous-HSCT remains unclear in Europe. Our study on 2697 autologous-HSCT performed in adults in 17 Belgian centres (2007–2013) aims at comparing the adjusted 1 and 3-yr survival between the different centres & investigating the impact of 3 centre-related factors on performance (time between JACIE accreditation achievement by the centre and the considered transplant, centre activity volume and type of HSCT performed by centres: exclusively autologous vs both autologous & allogeneic). We showed a relatively homogeneous performance between Belgian centres before national completeness of JACIE implementation. The 3 centre-related factors had a significant impact on the 1-yr survival, while activity volume and type of HSCT impacted the 3-yr survival of autologous-HSCT patients in univariable analyses. Only activity volume (impact on 1-yr survival only) and type of HSCT (impact on 1 and 3-yr survivals) remained significant in multivariable analysis. This is explained by the strong relationship between these 3 variables. An extended transplantation experience, i.e., performing both auto & allo-HSCT, appears to be a newly informative quality indicator potentially conveying a multitude of underlying complex factors.

Original languageEnglish
Pages (from-to)1434-1442
Number of pages9
JournalBone Marrow Transplantation
Issue number9
Publication statusPublished - 1 Sep 2019

ID: 45501502